State Street heads into the back half of August with an interesting split: short sellers are backing away at a meaningful pace, yet options traders are the most defensively positioned they have been in months.
The clearest divergence this week sits in the options market. The put/call ratio has climbed to 0.83 — nearly 1.8 standard deviations above its 20-day average of 0.74. That is the most defensive reading in the recent range, and the drift has been consistent: the PCR has ticked higher every session since early August, rising from 0.69 on August 5 to 0.83 by August 14. It falls well short of the 52-week extreme of 1.50, but the directional move is notable, suggesting investors are adding downside protection even as the stock itself has gained 3.8% on the week to close at $191.74.
Short interest tells a contrasting story. Bears have pulled back sharply — SI dropped roughly 14% over the past week to just 1.7% of the free float, its lowest level in the 30-day window. That follows a brief buildup through late July that has since unwound entirely. The lending market reflects the same disinterest: borrow availability is extraordinarily loose at over 4,500% of short interest, meaning there are roughly 45 shares available to lend for every one currently borrowed. Cost to borrow is near zero at 0.38%, down sharply over the week. There is no squeeze dynamic here, and no signal of fresh conviction on the short side.
The Street has been broadly constructive on the back of Q2 results. After the July 16 print, nearly every major firm lifted its target — Morgan Stanley moved to $195 from $183, Wells Fargo to $215 from $196, Citigroup to $210 from $193, and Keefe Bruyette to $215 from $195. JP Morgan followed up on August 4, lifting its target to $187 while staying at Neutral — a more cautious data point from a firm that sits below the consensus mean price target of $199.50. With the stock at $191.74, it is now trading above JP Morgan's ceiling and within striking distance of the broader consensus, which frames the near-term return potential as modest unless the October earnings print delivers a fresh catalyst. Factor scores support a measured read: EPS momentum is strong — ranking in the 90th percentile over 30 days and 84th over 90 days — but the forward growth score sits at just 44, and the analyst recommendation differential is neutral at 48.
The institutional ownership picture adds a subtle note of interest. FMR added nearly 1.9 million shares in the most recent reporting period, making it one of the more active builders among the top holders. Victory Capital added over 2.5 million shares — a substantial move relative to its existing position. BlackRock added modestly at 435,000 shares. Against that, Vanguard Portfolio Management trimmed by 1.4 million shares. The net flow from large institutions looks more constructive than cautious, which sits somewhat at odds with the options positioning drift.
On the insider side, the recent activity is uniformly on the sell side. CEO Ronald O'Hanley sold 14,553 shares on July 21 at $184.17, adding to an earlier May sale at $155.35. The Chief Risk Officer and HR Director both sold material blocks over the same period. The 90-day net insider position is technically positive at around 64,000 shares in net terms, but a closer look at the individual trades shows the net figure is an artifact of how the data aggregates — the observable recent activity has been consistent selling from senior management as the stock has re-rated higher. Q3 results on October 14 now represent the next test of whether the fundamental picture justifies a stock that has risen 43% year-to-date, and whether the options market's recent defensiveness proves well-timed or fades back toward the year's low PCR readings.
See the live data behind this article on ORTEX.
Open STT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
